Physician profile
Brian P First
NPI 1770531816
$14,813.55
in general payments reported to CMS, 2019-2025
72 companies · $2,575 in 2025
The $2,575 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $1,038 · 2021: $2,393 · 2022: $2,748 · 2023: $2,286 · 2024: $2,674 · 2025: $2,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,481 · Education: $53.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,480.92 |
| Education | $53.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,644.68 | 2019-2025 | Repatha, Evenity, Tepezza |
| Abbvie INC. | $1,025.80 | 2019-2025 | |
| Novo Nordisk INC | $998.21 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $797.20 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $757.03 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $738.53 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Nestle Healthcare Nutrition INC. | $613.62 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.19 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Mannkind Corporation | $571.40 | 2019-2025 | Afrezza |
| Novartis Pharmaceuticals Corporation | $470.90 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $429.10 | 2019-2023 | |
| Dexcom, INC. | $375.32 | 2019-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $363.50 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $323.60 | 2021-2025 | |
| Eisai INC. | $305.30 | 2021-2025 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $304.74 | 2019-2025 | Omnipod |
| Janssen Biotech, INC. | $290.00 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Cequr Corporation | $255.88 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $250.89 | 2020-2024 | Freestyle Libre 3, Octrode |
| Pfizer INC. | $247.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $246.78 | 2019-2022 | |
| Beta Bionics, INC. | $240.44 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $221.13 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $191.40 | 2021-2025 | Minimed 780g |
| Kowa Pharmaceuticals America, INC. | $169.07 | 2024-2025 | Zoryve |
| Madrigal Pharmaceuticals | $164.36 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $158.25 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Aimmune Therapeutics, INC. | $107.49 | 2024-2025 | Zenpep |
| Sunovion Pharmaceuticals INC. | $98.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $95.50 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.84 | 2020-2024 | Eohilia |
| Celltrion USA INC. | $92.19 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $90.08 | 2019-2025 | Evkeeza, Dupixent |
| Biohaven Pharmaceutical Holding Company Ltd. | $84.90 | 2022 | |
| Romark Laboratories, Lc | $78.09 | 2019-2020 | |
| Zealand Pharma US, INC. | $73.16 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $69.08 | 2019-2023 | Ocaliva |
| Biohaven Pharmaceuticals, INC. | $58.70 | 2021 | |
| Kyowa Kirin, INC. | $56.93 | 2025 | |
| Amarin Pharma, INC. | $56.47 | 2020-2022 | |
| Daiichi Sankyo INC. | $55.55 | 2020-2022 | |
| Shire North American Group INC | $55.47 | 2019 | |
| Phathom Pharmaceuticals, INC. | $53.02 | 2023-2024 | Voquezna |
| Ibsa Pharma INC. | $50.64 | 2020-2025 | Tirosint, Licart, Flector |
| Impel Pharmaceuticals INC. | $47.12 | 2022-2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $46.43 | 2022 | |
| Idorsia Pharmaceuticals US INC | $45.76 | 2023-2024 | Quviviq |
| Philips North America LLC | $43.92 | 2024-2025 | Extended Holter, (Ck7) Extended Holter |
| Biogen, INC. | $43.45 | 2023-2024 | Leqembi, Spinraza |
| Allergan, INC. | $43.16 | 2019-2020 | |
| Antares Pharma, INC. | $38.99 | 2022 | |
| Cmp Pharma, INC. | $35.32 | 2021 | |
| Valeritas, INC. | $33.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.61 | 2019 | |
| Ascendis Pharma Endocrinology INC | $28.48 | 2025 | Yorvipath |
| Braintree Laboratories, INC. | $28.17 | 2022 | |
| Fresenius Kabi USA, LLC | $25.02 | 2024 | Idacio |
| Horizon Therapeutics Plc | $24.26 | 2021 | |
| Halozyme INC | $23.33 | 2023 | |
| Sequel Med Tech, LLC | $23.24 | 2025 | Twiist |
| Boston Scientific Corporation | $23.01 | 2022 | |
| Nevro Corp. | $22.01 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.98 | 2019 | |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Companion Medical, INC. | $19.73 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.94 | 2025 | Azmiro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.41 | 2022 | |
| Corcept Therapeutics | $16.67 | 2025 | Korlym |
| Phadia US INC. | $16.53 | 2024 | Immunocap |
| Astellas Pharma US INC | $14.48 | 2019 | |
| Esperion Therapeutics, INC. | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,865.52 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian First listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.